A Phase I Open-Label, Dose-Escalating, Multi-Center Trial to Evaluate the Safety and Tolerability of Topical Ocular PAN-90806 in Patients with Neovascular Age-Related Macular Degeneration (AMD)

Administered By

Awarded By

Contributors

Start/End

  • March 25, 2014 - April 1, 2019